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In our study [1] the Bladder Cancer Molecular Taxonomy
Group collaborated to extend a first consensus report [2],
addressing the need for a consensus molecular classification
for muscle-invasive bladder cancer (MIBC) that would
support basic research and clinical trials. We provide such
a consensus classification and offer a single-sample classifier
(http://cit.ligue-cancer.net:3838/apps/consensusMIBC_web).
Yatai et al [3] acknowledge the need for an MIBC
consensus classification and commend our efforts, but
suggest limitations in our methodology and data. Our
discussion [1] acknowledged limitations related to cohorts,
expression assays, and clinical data. Here, we would like to
respond to several statements by Yatai et al, as thesewere at
times imprecise [120_TD$DIFF], or based onmisinterpretation or on results
that we reported but were overlooked.
First, we would like to clarify our methodological
approach and goals. Using historical transcriptomic data
from diverse sources and technologies from 1750 tumors
and 18 data sets, we identified a consensus of six published
MIBC classifications. Aware of concerns about using data
from different microarray platforms, or RNA sequencing
(RNA-seq) and microarray data, we did not aggregate the
18 data sets; instead, we ran the six classifiers on each data
set independently (Section 2.2, Supplementary Fig. 1 [1])
and then jointly analyzed the six resulting partitions of the
1750 tumors using an approach similar to that described for
colorectal cancer [4]. While we emphasized describing the
consensus results, we provided classification results for all
samples in each of the 18 data sets (Supplementary Fig. 7
[1]). We trained the single-sample classifier on a subset of
the microarray [5] and RNA-seq [6] data and then applied it
to all remaining samples. We reported performancemetrics
for the classifier (Supplementary Fig. 9C [1]) and showed
that it can be used with both microarray and RNA-seq data.
We also tested COCA, which clusters per-sample classifica-
tion calls (eg, Fig. 6A in [6]); for conciseness, we did not
report these results.
Yatai et al state that Guinney’s approach [4] “has not
always been successful in other cancers”, but do not
reference this claim. We are aware of two publications
that use this consensus subtype approach: the original
2015 work (n [121_TD$DIFF]= 4151) [4], and our work on MIBC (n [122_TD$DIFF]= 1750)
[1]. Two other recent studies used different methods to
generate single-sample classifiers from subtypes for several
separate data sets. Chen et al [7] worked with microarray
data from 15 ovarian cancer data sets (n [123_TD$DIFF]= 1774), while
Rashid et al [8] worked with microarray and RNA-seq data
(n [124_TD$DIFF]= 1085) from nine pancreatic cancer data sets. In both
studies, classifier features were binary gene pairs for
subsets of genes.
Our main goals were to help the development of MIBC
precision medicine by providing a robust framework to
connect retrospective and prospective clinical findings to
molecular contexts, and to identify clinically relevant
biomarkers for patient management. Our goals did not
include proposing or comparing methods for deriving a
consensus from different classification solutions.
Second,wewould like to respond to specific criticisms by
making several points.
 Bladder cancer is a complex disease, pathologically,
clinically, and biologically, and it would be naïve to think
that the six consensus classes will capture all of this
complexity. Furthermore, any parameter such as treat-
ment response in the presence of a specific mutated gene
may need to be tested across subtypes [125_TD$DIFF], because the
response may vary by subtype.
 The pathological, clinical, and biological characteristics of
the consensus subtypes identified are consistent with
previous findings, providing additional confidence in our
consensus approach. For example, the associations be-
tween histological variants were particularly interesting
for the squamous variant and the neuroendocrine variant,
which were strongly associated with the basal/squamous
and the neuroendocrine-like subtypes, respectively.
 While we reported subtype associations for four histo-
logical variants (squamous, micropapillary, sarcomatoid,
and neuroendocrine), sample sizes prevented us from
reporting associations for rarer variants such as plasma-
cytoid. Future studies are needed to determine whether
rarer variants fit within our consensus groups or define
additional molecular classes.
 To increase the sample sizes for reporting subtype-
specific genetic alterations for seven key bladder-cancer
genes, including FGFR3, TP53, and RB1, we used data for
copy number, gene fusions, and gene mutations from
600 samples from the 18 cohorts. This allowed us to show
that TP53 and RB1 genetic alterations co-occurred in 16 of
the 17 neuroendocrine-like tumors that had both
sequencing and copy number data (Fig. 3B [1]).
 Yatai et al state that “while 23 enriched genes were
reported, it was not verified whether these enriched
genes were (up) activated or (down) inactivated”.
Figure 2C [1] reports p values for “associations between
each consensus class and the activity status of 23 reg-
ulons”, as we described in the Methods section. For
example, the PPARG regulon is activated in the luminal
subtypes and the FOXM1 regulon in the basal/squamous
subtype. Regulon activities have been validated in
17 TCGA (The Cancer Genome Atlas) cohorts [9] and
with in vitro knockdown assays [10].
 Yatai et al also state the need to investigate the prognostic
value of molecular subtypes, citing work (their reference
[5]) that considered what may help surgeons decide
between partial and radical cystectomy for patients
diagnosed with bladder-adherent colorectal carcinoma.
We find that this colorectal cancer citation lacks relevance
to our work, which applies to patients with primary
urothelial bladder cancer.
 We analyzed treatment response according to the consen-
sus classes in retrospective series, discussed selection of
patients for anti-FGFR treatments, and suggested thera-
peutic targets for each class. We reported biological
subtype characteristics that may have clinical value (Fig.
5C [1]). Several publications [6,11,12] reported on the
prognostic value of individual subtypes and on their
possible predictive value for response to chemotherapy
and immunotherapy, or suggestedproposed treatments by
subtype as a roadmap for clinical testing and validation
[6]. We found no significant association between subtypes
and pathological neoadjuvant chemotherapy (NAC) re-
sponse (or survival after NAC) in this larger data set, and
suggest that future studies investigate this issue in the
context of the consensus classes.
We reiterate what we stated in our article [1]: there is an
outstanding need, but also an opportunity, for the MIBC
community to use and validate these consensus subtypes in
completed and ongoing prospective clinical trials.
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